BR Biopharma (NASDAQ:BRBI) Stock Price Up 0.2% – Still a Buy?

BR Biopharma, Inc. (NASDAQ:BRBI)’s stock price shot up 0.2% on Tuesday . The stock traded as high as $16.39 and last traded at $16.39. 1,224 shares changed hands during mid-day trading, a decline of 73% from the average session volume of 4,502 shares. The stock had previously closed at $16.35.

Analyst Ratings Changes

Separately, Weiss Ratings began coverage on BR Biopharma in a research report on Friday, February 13th. They set a “sell (e-)” rating for the company. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

BR Biopharma Stock Performance

The stock has a fifty day simple moving average of $14.79.

BR Biopharma (NASDAQ:BRBI) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported $0.16 earnings per share (EPS) for the quarter. The firm had revenue of $23.81 million during the quarter.

About BR Biopharma

BRBI BR Partners SA, through its subsidiaries, operates as an investment bank which specializes in providing financial services for entrepreneurs and families principally in Brazil. It offers financial advisory services for mergers and acquisitions, capital markets, board services, shareholders, special situations and restructuring, pre-IPO, and privatization; and wealth management services. BRBI BR Partners SA is based in S?o Paulo, Brazil.